Cardiac Involvement in Granulomatosis with Polyangiitis

Lucy McGeoch1, Simon Carette1, David Cuthbertson1

  • 1From the Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada; Health Informatics Institute, University of South Florida, Tampa, Florida; Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio, USA; Division of Rheumatology, McMaster University, Hamilton, Ontario, Canada; Division of Rheumatology, University of Utah, Salt Lake City, Utah; Division of Rheumatology, University of Pennsylvania, Philadelphia; Division of Rheumatology, University of Pittsburgh, Pennsylvania; The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Division of Pulmonary and Critical Care Medicine, and the Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.L. McGeoch, MD; S. Carette, MD, Division of Rheumatology, Mount Sinai Hospital; D. Cuthbertson, MS, Health Informatics Institute, University of South Florida; G.S. Hoffman, MD, Center for Vasculitis Care and Research, Cleveland Clinic; N. Khalidi, MD, Division of Rheumatology, McMaster University; C.L. Koening, MD, Division of Rheumatology, University of Utah; C.A. Langford, MD, Center for Vasculitis Care and Research, Cleveland Clinic; C.A. McAlear, MA, Division of Rheumatology, University of Pennsylvania; L. Moreland, MD, Division of Rheumatology, University of Pittsburgh; P.A. Monach, MD, PhD, The Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine; P. Seo, MD, Division of Rheumatology, Johns Hopkins University; U. Specks, MD, Division of Pulmonary and Critical Care Medicine; S.R. Ytterberg, MD, Division of Rheumatology, Mayo Clinic College of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology, University of Pennsylvania; C. Pagnoux, MD, MSc, MPH, Division of Rheumatology, Mount Sinai Hospital.

Summary

Cardiac involvement in granulomatosis with polyangiitis (GPA) is rare, affecting 3.3% of patients in a North American cohort. This cardiac complication did not increase relapse rates or premature death.

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
955
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
612
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
855
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
327
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
775